Creation of Ternary Multicomponent Crystals by Exploitation of Charge‐Transfer Interactions
Authors:
- 21 June 2013
- journal article
- research article
- Published by Wiley in Chemistry – A European Journal
- Vol. 19 (32) , 10663-10671
Abstract
Four new ternary crystalline molecular complexes have been synthesised from a common 3,5‐dinitrobenzoic acid (3,5‐dnda) and 4,4′‐bipyridine (bipy) pairing with a series of amino‐substituted aromatic compounds (4‐aminobenzoic acid (4‐aba), 4‐(N,N‐dimethylamino)benzoic acid (4‐dmaba), 4‐aminosalicylic acid (4‐asa) and sulfanilamide (saa)). The ternary crystals were created through the application of complementary charge transfer and hydrogen‐bonding interactions. For these systems a dimer was created through a charge‐transfer interaction between two of the components, while hydrogen bonding between the third molecule and this dimer completed the construction of the ternary co‐crystal. All resulting structures display the same acid⋅⋅⋅pyridine interaction between 3,5‐dnba and bipy. However, changing the third component causes the proton of this bond to shift from neutral OH⋅⋅⋅N to a salt form, O−⋅⋅⋅HN+, as the nature of the group hydrogen bonding to the carboxylic acid was changed. This highlights the role of the crystal environment on the level of proton transfer and the utility of ternary systems for the study of this process.Keywords
This publication has 61 references indexed in Scilit:
- The role of cocrystals in pharmaceutical scienceDrug Discovery Today, 2008
- Polymorphism in Carbamazepine CocrystalsCrystal Growth & Design, 2008
- Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution ratesAdvanced Drug Delivery Reviews, 2007
- Cocrystal or Salt: Does It Really Matter?Molecular Pharmaceutics, 2007
- The Salt−Cocrystal Continuum: The Influence of Crystal Structure on Ionization StateMolecular Pharmaceutics, 2007
- Pharmaceutical Co-CrystalsJournal of Pharmaceutical Sciences, 2006
- Crystal engineering of pharmaceutical co-crystals from polymorphic active pharmaceutical ingredientsChemical Communications, 2005
- Crystal engineering of the composition of pharmaceutical phases. Do pharmaceutical co-crystals represent a new path to improved medicines?Chemical Communications, 2004
- Solvent-drop grinding: green polymorph control of cocrystallisationElectronic supplementary information (ESI) available: additional powder XRD patterns. See http://www.rsc.org/suppdata/cc/b4/b400978a/Chemical Communications, 2004
- High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solidsAdvanced Drug Delivery Reviews, 2004